New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
10:10 EDTREGN, REGN, REGN, SNY, SNY, SNYSanofi to co-host a conference call with Regeneron
Sanofi and Regeneron co-host a conference call during the upcoming American Heart Association's Scientific Sessions which will focus on the LDL cholesterol-lowering PCSK9 Antibody (SAR236553/ REG727) on November 5 at 10:15 am. Webcast Link
News For REGN;SNY From The Last 14 Days
Check below for free stories on REGN;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
07:32 EDTREGNRegeneron may be taking market share from Roche, says Brean Capital
Subscribe for More Information
05:20 EDTREGNRegeneron initiated with a Buy at Canaccord
Subscribe for More Information
April 15, 2014
06:32 EDTSNYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 11, 2014
07:06 EDTSNYVIVUS announces avanafil clinical data presentation
Subscribe for More Information
April 9, 2014
07:09 EDTSNYReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
April 8, 2014
11:03 EDTREGN, SNYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 7, 2014
05:28 EDTSNYGenzyme to resubmit Lemtrada application for FDA review
Subscribe for More Information
April 3, 2014
06:36 EDTSNYSanofi on lookout for acquisitions, expects growth in Africa, Reuters says
Subscribe for More Information
06:28 EDTREGNAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use